论文部分内容阅读
目的:探讨重组人血管内皮抑素(恩度)联合顺铂抑制小鼠肺转移癌的作用和机制。方法:取H22肝癌细胞株腹水瘤反复从小鼠尾静脉注入,建立高肺转移小鼠模型,随机分为4组:生理盐水、顺铂、恩度和顺铂与恩度联合治疗组,10只/组。从尾静脉接种后第7天腹腔内给药,1次/d,连用14 d,第21天处死,解剖出小鼠肺脏,称质量,计数肺转移结节数,并对肺转移瘤组织进行免疫组化染色,检测血管内皮生长因子(VEGF)表达,计数微血管密度。结果:生理盐水组、恩度组、顺铂组和联合治疗组肺转移率分别为100%、70%、60%和40%,肺转移结节数分别为(28.6±10.2)、(20.7±5.6)、(14.3±6.4)和(8.9±3.8)个,微血管密度计数为(31.4±3.1)、(24.6±5.9)、(21.2±4.7)和(15.2±3.1),各治疗组结果与生理盐水组比较差异均有统计学意义(P<0.05),联合组与顺铂组或恩度组比较也具有差异(P<0.05)。生理盐水组肺转移瘤组织的VEGF表达明显高于各治疗组(P<0.05)。结论:恩度单用或联合顺铂均能显著抑制H22肝癌肺转移组织的血管生成,降低了肺转移。
Objective: To investigate the effect and mechanism of recombinant human endostatin (Endostar) combined with cisplatin on lung metastasis of lung cancer in mice. Methods: H22 hepatocellular carcinoma cell line ascites was injected repeatedly from the tail vein of mice to establish a mouse model of high lung metastasis. The mice were randomly divided into 4 groups: normal saline, cisplatin, Endostar and cisplatin combined with Endostar, 10 /group. From the tail vein on the 7th day after intraperitoneal administration, 1 / d, once every 14 d, the first 21 days were sacrificed, the lungs of mice were dissected, weighed, the number of lung metastases were counted, and lung metastases were performed Immunohistochemical staining, detection of vascular endothelial growth factor (VEGF) expression, counting microvessel density. Results: The lung metastasis rates were 100%, 70%, 60% and 40% in NS group, Endeng group, cisplatin group and combination group respectively. The number of lung metastasis was (28.6 ± 10.2) and (20.7 ± (14.3 ± 6.4) and (8.9 ± 3.8). The microvessel density count was (31.4 ± 3.1), (24.6 ± 5.9), (21.2 ± 4.7) and (15.2 ± 3.1) There was significant difference between the saline group and the cisplatin group or Ende group (P <0.05). The expression of VEGF in NSCLC group was significantly higher than that in each treatment group (P <0.05). Conclusions: Endostar alone or combined with cisplatin can significantly inhibit angiogenesis in lung metastasis of H22 hepatocellular carcinoma and reduce lung metastasis.